EHC Stock - Encompass Health Corporation
Unlock GoAI Insights for EHC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.37B | $4.80B | $4.35B | $4.01B | $3.57B |
| Gross Profit | $2.23B | $1.98B | $1.75B | $1.70B | $3.40B |
| Gross Margin | 41.6% | 41.3% | 40.3% | 42.4% | 95.2% |
| Operating Income | $864.50M | $1.72B | $630.20M | $659.40M | N/A |
| Net Income | $455.70M | $352.00M | $271.00M | $412.20M | $284.20M |
| Net Margin | 8.5% | 7.3% | 6.2% | 10.3% | 8.0% |
| EPS | $4.53 | $3.54 | $2.72 | $4.15 | $2.87 |
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families. As of June 1, 2022, it operated 149 hospitals, 252 home health locations, and 99 hospice locations in 42 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 11th 2024 | KeyBanc Capital Markets | Initiation | Overweight | $115 |
| July 10th 2024 | Leerink Partners | Initiation | Outperform | $100 |
| March 6th 2024 | Barclays | Initiation | Overweight | $95 |
| March 14th 2023 | Barclays | Initiation | Equal Weight | $57 |
Earnings History & Surprises
EHCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $1.29 | — | — | — |
Q4 2025 | Oct 29, 2025 | $1.19 | $1.23 | +3.4% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $1.23 | $1.40 | +13.8% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $1.19 | $1.37 | +15.1% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $1.05 | $1.17 | +11.4% | ✓ BEAT |
Q4 2024 | Oct 28, 2024 | $0.94 | $1.03 | +9.6% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $1.01 | $1.11 | +9.9% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.94 | $1.12 | +19.1% | ✓ BEAT |
Q1 2024 | Feb 7, 2024 | $0.82 | $0.95 | +15.9% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.77 | $0.86 | +11.7% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.75 | $0.95 | +26.7% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $0.70 | $0.88 | +25.7% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $0.83 | $0.88 | +6.0% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $0.64 | $0.67 | +4.7% | ✓ BEAT |
Q3 2022 | Aug 1, 2022 | $0.97 | $0.89 | -8.2% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $0.92 | $0.97 | +5.4% | ✓ BEAT |
Q1 2022 | Feb 1, 2022 | $1.05 | $0.97 | -7.6% | ✗ MISS |
Q4 2021 | Oct 27, 2021 | $1.06 | $1.03 | -2.8% | ✗ MISS |
Q3 2021 | Jul 27, 2021 | $0.97 | $1.17 | +20.6% | ✓ BEAT |
Latest News
Encompass Health Reaffirms Full-Year 2025 Guidance; Net Operating Revenue Of $5.905B-$5.955B; Adjusted EBITDA Of $1.235B-$1.255B; Adjusted EPS From Continuing Operations Attributable To Encompass Health Of $5.22-$5.37
📈 PositiveBarclays Maintains Overweight on Encompass Health, Raises Price Target to $150
📈 PositiveEncompass Health shares are trading lower after the company reported mixed Q3 financial results and narrowed its FY25 sales guidance.
📉 NegativeEncompass Health Raises FY2025 Adj EPS Guidance from $5.12-$5.34 to $5.22-$5.37 vs $5.28 Est; Narrows FY2025 Sales Guidance from $5.880B-$5.980B to $5.905B-$5.955B vs $5.935B Est
📈 PositiveEncompass Health Q3 Adj. EPS $1.23 Beats $1.20 Estimate, Sales $1.478B Miss $1.480B Estimate
📈 PositiveUBS Maintains Buy on Encompass Health, Raises Price Target to $150
📈 PositiveKeybanc Maintains Overweight on Encompass Health, Raises Price Target to $140
📈 PositiveEncompass Health Affirms FY2025 Adj EPS Guidance of $5.12-$5.34 vs $5.28 Est; Affirms FY2025 Sales Guidance of $5.880B-$5.980B vs $5.935B Est
📈 PositiveB of A Securities Maintains Buy on Encompass Health, Raises Price Target to $160
📈 PositiveFrequently Asked Questions about EHC
What is EHC's current stock price?
What is the analyst price target for EHC?
What sector is Encompass Health Corporation in?
What is EHC's market cap?
Does EHC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EHC for comparison